Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

News
On October 1, Celldex Therapeutics, Inc. announced the successful completion of its acquisition of CuraGen Corporation. The purchase price for CuraGen was approximately $93.5 million and, as a result of the merger, CuraGen has become a wholly owned subsidiary of Celldex. The acquisition adds a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform.

WilmerHale represented CuraGen in this transaction. The WilmerHale team included Lara Mataac and Ravi Faiia from the Corporate Group, and Kimberly Wethly from the Tax Group. William Schmidt advised on employee benefits, Sally Byrne advised on licensing and Michael Twomey advised on patent matters.